Efficacy of a Tbo-Filgrastim Protocol for Stem Cell Engraftment in Autologous Stem Cell Transplant

Abstract

correction of our HCT-CI workflow initiates a precise process for scoring and reporting of comorbidities. We expect our novel quality improvement process to provide a superlative data management tool for future quality improvement initiatives in service of our patients, as we have recently demonstrated in the management of acute graft vs. host disease (Ravulapati et al, 2016).